Balasar Mehmet, Doğan Metin, Kandemir Abdulkadir, Taskapu Hakan Hakki, Cicekci Faruk, Toy Hatice, Gurbuz Recai
Department of Urology, Meram Medical School, Necmettin Erbakan University Konya, Turkey.
Department of Medical Microbiology, Meram Medical School, Necmettin Erbakan University Konya, Turkey.
Int J Clin Exp Med. 2014 Jun 15;7(6):1554-7. eCollection 2014.
In the present manuscript, we studied the incidence of granulomatous prostatitis in the prostatectomy specimen of the patients who underwent transurethral resection of the prostate (TURP) after superficial bladder cancer treatment with intravesical Bacillus Calmette-Guerin (BCG) and were diagnosed with benign prostate hyperplasia (BPH). The clinical data and histopathological specimen records of 472 patients who underwent TUR-P due to BPH diagnosis, obtained over a period of 6 years in the urology department of Private Konya Hospital, Konya, Turkey, were studied retrospectively. The cases were divided into two groups as (Group I) who did not undergo any treatment and as (Group II) who underwent BCG treatment. The frequency and the clinical course of the cases with granulomatous prostatitis were studied histopathologically. There were in total 472 patients who underwent TUR-P. Out of the 459 patients who did not undergo BCG treatment (Group I), the histopathological specimen records of 262 (57%) was BPH, of 197 (43%) BPH + chronic prostatitis. Of the second group, 13 cases underwent intravesical BCG treatment before surgical intervention due to superficial bladder CA diagnosis. In this group 4 of the cases were diagnosed as (30%) BPH, 9 as (70%) chronic prostatitis + BPH. 6 out of the 9 chronic prostatitis cases were chronic prostatitis, 2 caseous granulomatous prostatitis, 1 non-caseous granulomatous prostatitis. Granulomatous prostatitis cases should require no specific therapy.
In patients with obstruction complaints following intravesical BCG treatment, granulomatous prostatitis should also be considered and treatment plans should be made accordingly.
在本手稿中,我们研究了经尿道前列腺切除术(TURP)的患者前列腺切除标本中肉芽肿性前列腺炎的发生率,这些患者在浅表性膀胱癌经膀胱内卡介苗(BCG)治疗后被诊断为良性前列腺增生(BPH)。回顾性研究了土耳其科尼亚市私立科尼亚医院泌尿外科在6年期间获得的472例因BPH诊断而接受TUR-P的患者的临床资料和组织病理学标本记录。病例分为两组,(第一组)未接受任何治疗的患者,以及(第二组)接受BCG治疗的患者。对肉芽肿性前列腺炎病例的频率和临床病程进行了组织病理学研究。共有472例患者接受了TUR-P。在未接受BCG治疗的459例患者(第一组)中,262例(57%)的组织病理学标本记录为BPH,197例(43%)为BPH + 慢性前列腺炎。第二组中,13例患者因浅表性膀胱癌诊断在手术干预前接受了膀胱内BCG治疗。在该组中,4例患者被诊断为(30%)BPH,9例为(70%)慢性前列腺炎 + BPH。9例慢性前列腺炎病例中,6例为慢性前列腺炎,2例为干酪样肉芽肿性前列腺炎,1例为非干酪样肉芽肿性前列腺炎。肉芽肿性前列腺炎病例无需特殊治疗。
在膀胱内BCG治疗后出现梗阻症状的患者中,也应考虑肉芽肿性前列腺炎,并应据此制定治疗计划。